Comprehensive medication guide to Levamlodipine including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay per month depending on plan; generic levamlodipine is typically Tier 2–3 on commercial formularies; brand-name Conjupri often requires prior authorization. Medicare Part D coverage varies by plan.
Estimated Cash Pricing
$413–$427 retail for brand-name Conjupri (5 mg, 30 tablets); generic levamlodipine maleate runs about $84–$86 retail, or as low as $70 with a free GoodRx or SingleCare coupon for a 30-day supply.
Medfinder Findability Score
62/100
Summarize with AI
On this page
Levamlodipine (brand name Conjupri) is a prescription antihypertensive medication approved by the FDA in December 2019. It belongs to the dihydropyridine calcium channel blocker (CCB) class and is indicated for the treatment of hypertension (high blood pressure) in adults and pediatric patients 6 years and older.
Levamlodipine is the purified (S)-enantiomer of amlodipine—the pharmacologically active half of the widely used blood pressure drug amlodipine (Norvasc). Because only the (S)-form blocks calcium channels, levamlodipine achieves equivalent antihypertensive effect at half the dose, with a significantly lower incidence of peripheral edema compared to racemic amlodipine.
The drug is available as Conjupri brand tablets (1.25 mg, 2.5 mg, 5 mg) and as generic levamlodipine maleate tablets. It is manufactured by CSPC Ouyi Pharmaceutical Co., Ltd. and marketed in the U.S. by Wraser Pharmaceuticals. It was first marketed in China under the trade name Xuanning since 2003.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Levamlodipine works by blocking L-type calcium channels in vascular smooth muscle cells. Calcium is required for smooth muscle contraction—when calcium flows into the cells of blood vessel walls through these channels, the vessels constrict and resistance increases. By blocking these channels, levamlodipine prevents calcium from entering, causing the smooth muscle to relax and the blood vessels to dilate (widen).
This vasodilation reduces peripheral vascular resistance and lowers blood pressure. Levamlodipine has greater selectivity for vascular smooth muscle than for cardiac muscle, so at therapeutic doses it typically does not significantly affect heart rate or cardiac contractility.
The drug has a long plasma half-life of approximately 30–50 hours, which supports once-daily dosing and consistent 24-hour blood pressure control. Peak plasma levels are reached 6–12 hours after oral administration, and steady-state is achieved after approximately 7–8 days of daily dosing.
1.25 mg — tablet
Starting dose for elderly patients and those with hepatic impairment; also used in pediatric patients 6-17 years
2.5 mg — tablet
Standard adult starting dose; most commonly available strength
5 mg — tablet
Maximum adult dose; used when 2.5 mg does not achieve blood pressure goal
Levamlodipine is not in an FDA-designated national drug shortage as of 2026. However, many patients find it difficult to fill at their local retail pharmacy. Because it is a newer medication (FDA approved December 2019) with a smaller prescribing base than generic amlodipine, most chain pharmacies do not routinely stock it on the shelf.
Patients who do find it typically succeed by: calling ahead to multiple pharmacies, asking for a special order (1-2 business days), using mail-order pharmacy, or trying independent pharmacies that stock a wider variety of medications. The 2.5 mg strength is the most commonly available; the 1.25 mg strength is the hardest to find.
The easiest solution is to use medfinder, which calls pharmacies near you to check real-time levamlodipine availability and texts you the results—saving the time and frustration of calling each pharmacy yourself.
Levamlodipine is not a controlled substance, so it can be prescribed by any licensed prescriber in the U.S. There are no DEA schedule requirements or special state prescription monitoring checks required. Any provider with prescribing authority who manages hypertension can write a levamlodipine prescription.
Primary care physicians (family medicine, internal medicine)
Cardiologists
Nephrologists
Endocrinologists
Nurse practitioners (NPs) — with full prescribing authority in most states
Physician assistants (PAs) — with prescribing authority per state regulations
Telehealth prescribing is fully available for levamlodipine. Because it is not a controlled substance, providers can prescribe it through any telehealth platform without additional DEA requirements. This makes it accessible through online hypertension management programs and insurance-based telehealth services.
No. Levamlodipine (Conjupri) is not a controlled substance and is not scheduled by the DEA. It is a standard prescription medication that can be prescribed by any licensed prescriber who manages hypertension, including primary care physicians, cardiologists, nurse practitioners, and physician assistants.
Because levamlodipine is not a controlled substance, there are no special DEA registration requirements for prescribers, no mandatory state prescription monitoring program checks, no restrictions on refills beyond standard prescription rules, and no quantity limits tied to controlled substance regulations. It can also be prescribed via telehealth without any additional requirements beyond standard prescribing rules.
Levamlodipine is generally well tolerated. The most commonly reported side effects include:
Peripheral edema (ankle/leg swelling) — less common than with amlodipine
Dizziness or lightheadedness
Fatigue
Flushing (warmth or redness in the skin)
Headache
Nausea
Severe hypotension (low blood pressure) — especially in patients with severe aortic stenosis
Worsening angina or myocardial infarction — most likely when first starting in patients with severe coronary artery disease
Severe allergic reactions or angioedema (swelling of face, lips, throat)
Hepatic enzyme elevations (rare; jaundice in very rare cases)
Know what you need? Skip the search.
Amlodipine (Norvasc)
The parent racemic compound; 5 mg amlodipine ≈ 2.5 mg levamlodipine in efficacy. Widely available generic, very inexpensive, but higher incidence of peripheral edema.
Felodipine
Another dihydropyridine CCB for hypertension; available as generic; may cause less edema than amlodipine.
Lisinopril (ACE inhibitor)
First-line antihypertensive; widely available generic; excellent tolerability except for dry cough in ~10-15% of patients.
Losartan (Cozaar/ARB)
ARB alternative for patients who can't tolerate ACE inhibitor cough; widely available generic; preferred in diabetes and kidney disease.
Prefer Levamlodipine? We can find it.
Dantrolene
majorContraindicated — risk of cardiovascular collapse and hyperkalemia when combined with calcium channel blockers.
Simvastatin (Zocor)
majorLevamlodipine inhibits CYP3A4 metabolism of simvastatin, increasing muscle toxicity risk. Limit simvastatin to 20 mg/day.
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir)
majorIncrease levamlodipine blood levels significantly; may require dose reduction and close BP monitoring.
Grapefruit / grapefruit juice
majorInhibits CYP3A4, increasing levamlodipine exposure. Avoid grapefruit products while taking this medication.
Sildenafil (Viagra)
moderateAdditive blood pressure lowering effect; monitor for dizziness, lightheadedness, or fainting.
CYP3A4 inducers (rifampin, St. John's Wort, carbamazepine)
moderateMay reduce levamlodipine effectiveness by accelerating its metabolism; monitor blood pressure closely.
NSAIDs (ibuprofen, naproxen)
moderateMay reduce antihypertensive effect and worsen fluid retention; use acetaminophen for pain when possible.
Levamlodipine (Conjupri) represents a meaningful refinement in antihypertensive therapy. By isolating the pharmacologically active enantiomer of amlodipine, it delivers equivalent blood pressure control at half the dose with significantly fewer peripheral edema side effects—a practical improvement that can meaningfully affect quality of life for patients who previously struggled with amlodipine-related swelling.
The primary challenge with levamlodipine in 2026 is not clinical efficacy—it's finding it. Many pharmacies don't routinely stock it, and it requires more effort to locate than its parent drug. Patients and providers need to be proactive: use mail-order pharmacy, set up standing orders, and leverage pharmacy-finding tools. With the right approach, consistent access is achievable.
If you've been prescribed levamlodipine and need help finding it at a pharmacy near you, medfinder calls pharmacies in your area to check real-time availability and texts you the results—so you can spend less time on hold and more time focusing on your health.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini